formance dialyzers, a higher molecular weight substance should be used to evaluate removal efficiency in evaluations of the performance of HDF, in which diffusion and convection are performed simultaneously.
In this paper, we state based on our own cases what kind of marker should be used and how conditions for HDF should be set up in order to make the best use of the distinctive features and benefits of HDF.
What Is a Suitable Biomarker for Evaluation of Clinical Outcomes of HDF?
On-line HDF became formally covered by the Japanese National Health Insurance system (JNHAS) in 2010. However, four conditions were stipulated for performing it: (1) use of approved dedicated HDF equipment, (2) use of an approved hemodiafilter, (3) guarantee of dialysis water purification by each institution, and (4) DA and dialysis difficulty as indications.
We changed the dialysis conditions at our own institution to conform to the conditions stipulated for coverage by JNHAS in 17 cases that had become stable on HDF with a super high-flux dialyzer, and the result was that by one month after changing the dialysis conditions, the symptoms in 13 of the 17 cases had become worse. In 6 of these 13 cases, the dialysis method had been changed to HD with a super high-flux dialyzer, and in the other 7 cases it had been changed to HDF with a hemodiafilter that had been approved.
We then changed the dialysis conditions again in the 13 cases in which the symptoms had become worse. More specifically, we attempted to improve removal performance of dialysis by performing HDF with the super high-flux dialyzer that had been used before or performed HD with a higher performance super high-flux dialyzer, etc. The result was that one month later ADL had improved in 11 of the 13 cases, and their QOL had returned to its previous level. An improvement in QOL was also noted in the other 2 cases. α 1 -Microglobulin (α 1 -MG) removal rates in the 13 cases whose symptoms changed from 'stable' to 'worse' and then to 'improved' changed significantly almost exactly in tandem with the changes in symptoms from 35.5 ± 7.7 to 23.2 ± 4.9% and then to 32.3 ± 5.6% (n = 13, all p < 0.01). However, the corresponding changes in Kt/V from 1.59 to 1.65 and then to 1.56 and in the β 2 -MG removal rate from 78.2 to 75.2% and then to 77.3% only fluctuated within narrow ranges. These changes show that the symptom worsening occurred because the α 1 -MG removal rate had decreased, i.e. they occurred because of insufficient removal of uremic toxins having a molecular weight of 30 kDa or more, and the improvement in symptoms occurred because the removal of uremic toxins having a molecular weight of 30 kDa or more had increased. They also showed that it is impossible to infer associations between changes in symptoms and LMWPs by assessing only Kt/V and β 2 -MG removal rates.
The symptoms that occurred were either the development or aggravation of bone and/or joint pain (10/13 cases), reduced activity (7/13 cases), pruritus (4/13 cases), RLS (3/13 cases), irritability (2/13 cases), etc. Dialysis vintage in these 13 cases was 21.0 ± 10.1 years, and dialysis vintage in the group that developed or experienced aggravation of bone and/or joint pain was 24.3 ± 9.0 years (group without these changes: 8.4 ± 4.1 years). When the dialysis vintages and the symptoms that developed were reviewed together, these episodes showed that continuing HDF at an α 1 -MG removal rate of 35% is advisable to prevent the onset of DA or mitigate these symptoms.
RLS symptoms have been classified into four stages by International Restless Legs Syndrome score (IRLS score): 1-10, mild; 11-20, moderate; 21-30, severe; 31-40, very severe [13] . Even a review of the IRLS score and α 1 -MG removal rate together in the 7 cases in which RLS developed as a complication revealed that while the symptoms were alleviated up to an α 1 -MG removal rate of 35%, the patients' RLS was not cured, and that an α 1 -MG removal rate of 38% or more was necessary in order to cure their RLS ( fig. 1 ). This shows that it is impossible to hope for a cure of RLS even by increasing removal of uremic toxins 66 from a molecular weight of 10-20 kDa, and that aggressively removing uremic toxins having molecular weights of 30 kDa or more leads to a cure of RLS [14] . These assessments showed that α 1 -MG should be used to correctly evaluate the distinctive features and benefits of HDF. 2 ). The predialysis α 1 -MG values of dialysis patients in our institution were 117.0 ± 19.9 mg/l (n = 126), and the mean value of healthy subjects was 12.5 ± 2.3 mg/l (n = 31). β 2 -MG is known to be the substance that causes DA, and many studies have been conducted regarding its etiology and β 2 -MG. β 2 -MG has a molecular weight of 11.8 kDa and a Stokes radius of 16 Å. The β 2 -MG predialysis values of dialysis patients in our institution were 26.5 ± 5.3 mg/l (n = 126), and the mean value of healthy subjects was 1.4 ± 0.3 mg/l (n = 31).
The changes in α 1 -MG and β 2 -MG values between August 2011 and August 2012 in all of the cases as a whole (n = 126) were: α 1 -MG, 119.8 → 117.0 mg/l, and β 2 -MG, 27.4 → 26.5 mg/l, and thus there was hardly any change in either of them. In an assessment of the HDF group (n = 11) alone, the changes were: α 1 -MG, 119.1 → 120.3 mg/l, and β 2 -MG, 24.0 → 22.9 mg/l, and a tendency for the β 2 -MG values to decrease was observed, but the difference was not significant.
Many studies have been conducted in this field since the Gejyo study in which β 2 -MG was identified as the precursor protein of DA, but no correlations have been reported between predialysis β 2 -MG values and the onset of DA or the severity of the symptoms [8, 9, [15] [16] [17] . Nor have there been any reports of studies that investigated the relationship between α 1 -MG and dialysis complications. Based on our study as well, at present predialysis α 1 -MG values have not been found to indicate the severity of the pathology or the appropriateness of the dialysis conditions, etc., but further study is needed.
Uremic toxins whose molecular weights are greater than that of β 2 -MG may be involved in the development of clinical manifestations such as insomnia, pruritus, irritability, RLS, anemia, and osteoarticular pain. For that reason, it has been said that it will be necessary to remove a wider range of LMWPs than β 2 -MG and to remove protein-bound toxins in order to treat these symptoms, and the same appeared to be true in the present study of our own cases.
We wish to emphasize that the reason for removing α 1 -MG is not because α 1 -MG itself is toxic, but because α 1 -MG has a molecular weight of 33 kDa and should be used as a biomarker for evaluation of clinical outcomes of HDF. We also concluded that an increase in therapeutic efficacy, an increase in patient QOL, and a higher survival rate can be expected when the distinctive features and advantages of HDF are best utilized by setting the HDF performance conditions with an α 1 -MG rate of 35% as the goal.
When HDF is performed under these conditions, a β 2 -MG removal rate of 80% can be easily achieved. On the other hand, even if the replacement fluid volume is increased, a β 2 -MG removal rate of 80% and α 1 -MG removal rate of 15% are likely to be achieved by HDF with a small-pore size dialyzer or hemodiafilter. line HDF were performed ( fig. 3 ) . Although there was a large amount of albumin loss when we performed HDF with each of the dialyzers, β 2 -MG removal rate was almost constant. This means that β 2 -MG is mainly removed by diffusion.
There is a twofold difference between the molecular weight of albumin (MW: 66 kDa, Stokes radius: 35.5 Å) and α 1 -MG, but there is a mere 20% difference in their Stokes radius. Because of the difference in their Stokes radius, it is impossible to differentially remove α 1 -MG and albumin with the dialysis membranes currently in use, and a correlation exists between the amount of α 1 -MG removed and the amount of albumin loss [18] . There is a strong likelihood that a certain degree of albumin loss has a positive impact on the body from the standpoint of removing uremic toxins that fall into the category of protein-bound solutes and of removing albumin that has lost its antioxidant capacity [19] [20] [21] .
Evaluation of Hemodiafilter Performance
We performed 50-liter predilution online HDF (for 4 h) at Q B 250 ml/min (Q D total 500 ml/min) with TDF-20H (Toray Medical Co., Ltd), ABH-21P (Asahi Kasei Medical Co., Ltd), and MFX-21U (Nipro Co.), and assessed removal performance ( fig. 4 ) . These three products can be described as high-performance versions of hemodiafilters that are currently on the market in Japan.
Under these assessment conditions, all three models yielded a good β 2 -MG removal rate of 80% [amount removed (mg): TDF, 186; ABH, 169; MFX, 190], but there were large differences in their α 1 -MG removal rates: TDF, 18.2% (amount removed: 93 mg), ABH, 25.9% (amount removed: 126 mg), and MFX, 37.5% (amount removed: 179 mg), respectively. Thus, differences between the performance of the hemodiafilters became in- 68 creasingly marked as molecular weight increased from the 11.8 kDa for β 2 -MG, to 23 kDa for prolactin, and to 33 kDa for α 1 -MG. If the removal performance of the hemodiafilters had been evaluated on the basis of β 2 -MG alone, the results for all three hemodiafilter models would have been the same. In other words, to make the best use of the distinctive features and benefits of HDF, it is important to use α 1 -MG as the biomarker to evaluate the removal performance of HDF, and to choose a hemodiafilter that provides an α 1 -MG removal rate of 35%. An improvement in clinical manifestations can be expected by doing so, and it increases patients' QOL and, in turn, their survival rate.
Conclusion
The removal performance of HDF should be assessed by using α 1 -MG as a biomarker. Further, the distinctive features and benefits of HDF are best utilized by selecting a suitable hemodiafilter and setting an α 1 -MG removal rate of 35% as the target value.
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